Evonik Strengthens Partnership with BioNTech on COVID-19 Vaccine

By Tim Wright, Editor, Contract Pharma | 02.12.21

Establishment of additional lipid production in Germany for use with mRNA-based vaccines.

Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech. This step contributes to increasing the supply security of the Pfizer-BioNTech COVID-19 vaccine.
 
"The pandemic requires decisive action," said Christian Kullmann, chairman of Evonik’s executive board. "We are therefore doing everything possible to supply our partners with the critical lipids they need. At the same time, we are expanding our production capacity and competencies along the entire value chain."
 
Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the strategic partnership between Evonik and the vaccine manufacturer BioNTech.
 
In mRNA-based vaccines, the mRNA is enclosed in a lipid nanoparticle (LNP) that is comprised of specific lipids. The LNP protects the mRNA and delivers it safely into the cell. There it is released so that the vaccine can exert its effect. Evonik has been a contract development and manufacturing organization (CDMO) leader for advanced drug delivery for many decades, supporting pharmaceutical companies worldwide in the development and production of complex parenteral drug products that require formulation technologies such as lipid nanoparticles.
 
The Germany-based company is one of the few integrated development and manufacturing partners for cell and gene therapies, and has been actively involved in various mRNA-based vaccines projects for COVID-19. 
 
"With our partnership with BioNTech, we are systematically expanding our leading position as an integrated development partner in cell and gene therapies," said Thomas Riermeier, head of Evonik's Health Care business line. Evonik’s portfolio includes pharmaceutical excipients such as lipids, as well as CDMO services for the formulation development, GMP manufacturing and aseptic filling of complex parenteral drug products.”